Matrifen

Fentanyl, the active ingredient in Matrifen, is an opioid analgesic presented as a transdermal patch for transdermal use. It treats severe chronic pain, cancer pain, and postoperative pain in patients who require continuous opioid therapy.

GNH USA supplies Matrifen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Fentanyl transdermal patches are indicated for management of severe persistent pain where continuous opioid delivery is required.

- Severe chronic pain: provides long‑acting analgesia for patients with chronic non‑cancer pain. - Cancer pain: delivers steady opioid levels to control moderate to severe cancer‑related pain. - Postoperative pain: used when oral analgesics are insufficient for postoperative pain management.

Fentanyl patches may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Constipation - Dizziness - Somnolence - Headache - Skin irritation at the patch site

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Adrenal insufficiency - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Opioid dependence or abuse - Cardiac arrhythmia

When prescribing fentanyl transdermal patches, careful assessment and monitoring are essential.

- Assess opioid tolerance: confirm patient has prior opioid exposure before initiating therapy. - Monitor respiratory function: watch for signs of respiratory depression, especially during dose changes. - Avoid use in severe respiratory disease: patients with COPD or sleep apnea require extra caution. - Use the lowest effective dose: titrate to achieve pain control while minimizing side effects. - Educate on disposal: advise proper patch removal and disposal to prevent accidental exposure. - Store at room temperature: keep in the original pouch, protect from moisture and heat.

Fentanyl interacts with several drug classes that can alter its safety or efficacy.

Major Interactions (Avoid): - Central nervous system depressants (e.g., benzodiazepines, barbiturates, alcohol): increased risk of respiratory depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, ritonavir): can raise fentanyl plasma levels. - Monoamine oxidase inhibitors (MAOIs): may precipitate severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may reduce fentanyl effectiveness. - CNS stimulants (e.g., certain antidepressants): may mask sedation. - Diuretics: can affect fluid balance and patch adhesion.